Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
NCT02754154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321182
Last updated 2022-05-09
Summary
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
Conditions
Interventions
- DRUG
-
Warfarin
- DRUG
-
Apixaban
- DRUG
-
Dabigatran
- DRUG
-
Rivaroxaban
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-12-31
- Primary Completion
- 2018-12-26
- Completion
- 2018-12-26
More Related Trials
-
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
NCT04249401 ·Status: COMPLETED
-
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134 ·Status: COMPLETED
-
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
NCT00787150 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
NCT02666157 ·Status: UNKNOWN ·Phase: PHASE4
-
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
NCT02061748 ·Status: COMPLETED
-
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
NCT02591732 ·Status: COMPLETED
-
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
NCT03792152 ·Status: UNKNOWN ·Phase: NA
-
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
NCT04878497 ·Status: UNKNOWN
-
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
NCT03026556 ·Status: COMPLETED
-
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
NCT06862726 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
NCT02982590 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
NCT03666962 ·Status: UNKNOWN
-
Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)
NCT02024230 ·Status: COMPLETED ·Phase: PHASE4
-
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
NCT03374540 ·Status: COMPLETED
-
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT00742859 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
NCT03572972 ·Status: COMPLETED
-
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
NCT02975453 ·Status: COMPLETED
-
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
NCT05051904 ·Status: COMPLETED
-
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
NCT04047654 ·Status: COMPLETED
-
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
NCT01674647 ·Status: COMPLETED ·Phase: PHASE3
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
NCT02295475 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
NCT00403767 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
NCT05973188 ·Status: UNKNOWN ·Phase: PHASE4
-
Specific Anti Factor Xa Activity Dosage to Enhance Detection of Nonadherence in Atrial Fibrillation Patients
NCT02925247 ·Status: COMPLETED ·Phase: NA